buflomedil buflomedil buflomedil names preferred iupac name 4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one identifiers cas number 55837-25-7 y 3d model (jsmol) interactive image chembl chembl188921 y chemspider 2373 y echa infocard 100.054.393 pubchem cid 2467 unii v7i71dq432 y comptox dashboard (epa) dtxsid5022697 inchi inchi=1s/c17h25no4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12h,4-10h2,1-3h3 ykey: owylaeyxiqkaol-uhfffaoysa-n yinchi=1/c17h25no4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12h,4-10h2,1-3h3key: owylaeyxiqkaol-uhfffaoyag smiles o=c(c1c(oc)cc(oc)cc1oc)cccn2cccc2 properties chemical formula c17h25no4 molar mass 307.38 g/mol pharmacology atc code c04ax20 (who) except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). y verify (what is yn ?) infobox references buflomedil, sold under the brand name loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. it is currently not approved by the food and drug administration (fda) for use in the united states. toxicity this drug has been suspended from marketing in the european union, because of concerns about severe neurological and cardiac toxicity. in its press release dated 17 november 2011 ema suggested that doctors "should stop using buflomedil and consider alternative treatment options". the european commission advised all member states to revoke marketing authorisation. various adverse effects have been reported to the fda. synthesis patent: china1 china2 acylation between 1,3,5-trimethoxybenzene (1) and 4-pyrrolidinobutyronitrile (2) occurs in chlorobenzene solvent in the presence of gaseous hydrochloric acid to give bufomedil (3). this is a demonstration of the hoesch reaction.